CRISPR

R&D

Decoding life: Key milestones in the CRISPR odyssey

The story of CRISPR’s development, from its humble beginnings as a bacterial defence mechanism to its current status as a groundbreaking tool for gene editing and beyond, is a fascinating j

R&D

Deep Dive: Research and Development 2024

In this edition of Deep Dive, delve into the revolutionary world of genetic editing as we trace the development of CRISPR, discover why Alexion’s Soraya Bekkali believes now it the time to champion

R&D

The opportunities and challenges facing rare disease therapi...

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.

R&D

The innovative future of CRISPR tech

CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA.

R&D

JP Morgan 2024 – Jonah Comstock talks with Trevor Martin

JP Morgan 2024 – Trevor Martin

Editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences

News

Intellia’s president and chief executive John Leonard

Intellia’s CRISPR drug could offer one-shot HAE treatment

A single dose of a gene-editing drug being developed by Intellia Therapeutics almost eliminated attacks in patients with hereditary angioedema (HAE) in a clinical trial, p